Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

TELA Bio stock

TELA
US8723811084
A2PUP9

Price

2.67
Today +/-
-0.09
Today %
-3.31 %

TELA Bio stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the TELA Bio stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the TELA Bio stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the TELA Bio stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze TELA Bio's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

TELA Bio Stock Price History

DateTELA Bio Price
2/6/20252.67 undefined
2/5/20252.76 undefined
2/4/20252.80 undefined
2/3/20252.72 undefined
2/2/20252.67 undefined
1/30/20252.64 undefined
1/29/20252.66 undefined
1/28/20252.77 undefined
1/27/20252.64 undefined
1/26/20252.67 undefined
1/23/20252.67 undefined
1/22/20252.65 undefined
1/21/20252.67 undefined
1/20/20252.63 undefined
1/16/20252.69 undefined
1/15/20252.66 undefined
1/14/20252.70 undefined
1/13/20252.74 undefined
1/12/20252.78 undefined

TELA Bio Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into TELA Bio, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by TELA Bio from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects TELA Bio’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of TELA Bio. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into TELA Bio’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing TELA Bio’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on TELA Bio’s growth potential.

TELA Bio Revenue, EBIT and net profit per share

DateTELA Bio RevenueTELA Bio EBITTELA Bio Net Income
2028e189.14 M undefined37.92 M undefined32.14 M undefined
2027e153.04 M undefined14.27 M undefined11.65 M undefined
2026e118.98 M undefined-7.01 M undefined-9.95 M undefined
2025e95.66 M undefined-20.99 M undefined-25.91 M undefined
2024e76.21 M undefined-32.16 M undefined-54.26 M undefined
202358.45 M undefined-44.08 M undefined-46.66 M undefined
202241.42 M undefined-39.01 M undefined-44.3 M undefined
202129.46 M undefined-29.45 M undefined-33.28 M undefined
202018.21 M undefined-25.28 M undefined-28.79 M undefined
201915.45 M undefined-19.16 M undefined-30.21 M undefined
20188.27 M undefined-19.94 M undefined-29.92 M undefined
20174.25 M undefined-16.92 M undefined-27.23 M undefined

TELA Bio Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20172018201920202021202220232024e2025e2026e2027e2028e
4815182941587695118153189
-100.0087.5020.0061.1141.3841.4631.0325.0024.2129.6623.53
50.0025.0060.0061.1162.0765.8568.9752.6342.1133.9026.1421.16
2291118274000000
-27-29-30-28-33-44-46-54-25-91132
-7.413.45-6.6717.8633.334.5517.39-53.70-64.00-222.22190.91
11.0111.0111.4112.9314.4716.2722.8700000
------------
Details

Keystats

ⓘ

Revenue and Growth

The TELA Bio Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the TELA Bio is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (k)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2017201820192020202120222023
             
11.3517.2854.5974.3943.9342.0246.73
0.761.32.842.684.236.629.74
0000000
1.824.354.63.917.6611.7913.16
0.430.332.312.243.232.022.1
14.3623.2664.3483.2259.0562.4571.73
1.160.760.680.631.192.913.94
0000000
0000000
03.222.912.612.32.52.12
0000000
2000000265
1.183.983.593.243.495.416.32
15.5427.2467.9386.4662.5467.8678.05
             
111.35124.150.010.010.020.020.02
00198.83245.74250.06288.36339.66
-108.17-137.86-167.86-196.65-229.93-274.23-320.89
00-20-70-5015091
0000000
3.18-13.7130.9649.0320.114.318.88
1.513.423.170.652.411.531.67
1.85.153.535.958.1610.8715.3
1.940.990.010000
0000000
910000000
6.169.566.716.610.5712.416.97
5.3131.3730.2430.8331.4939.9240.52
0000000
0.90.01000.381.231.69
6.2131.3830.2430.8331.8741.1542.2
12.3740.9436.9537.4342.4453.5559.17
15.5527.2367.9186.4662.5467.8578.05
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of TELA Bio provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand TELA Bio's financial health and stability.

Assets

TELA Bio's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that TELA Bio must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of TELA Bio after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into TELA Bio's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (k)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2017201820192020202120222023
-21-21-22-28-33-44-46
01,0000001,0000
0000000
0-4-60-3-5-2
443691112
0132234
0000000
-16-19-25-24-30-40-40
0-1-200-10
0-1-1190-10
00-99000
0000000
425000100
223654403446
2627654404046
--1.00----3.00-
0000000
952829-30-14
-16.48-21.48-28.22-24.63-31.06-42.62-41.47
0000000

TELA Bio stock margins

The TELA Bio margin analysis displays the gross margin, EBIT margin, as well as the profit margin of TELA Bio. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for TELA Bio.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the TELA Bio's sales revenue. A higher gross margin percentage indicates that the TELA Bio retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the TELA Bio's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the TELA Bio's total revenue generated. When comparing the revenue margin year over year, investors can gauge the TELA Bio's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the TELA Bio. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the TELA Bio's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

TELA Bio Margin History

TELA Bio Gross marginTELA Bio Profit marginTELA Bio EBIT marginTELA Bio Profit margin
2028e68.62 %20.05 %16.99 %
2027e68.62 %9.32 %7.61 %
2026e68.62 %-5.89 %-8.37 %
2025e68.62 %-21.94 %-27.08 %
2024e68.62 %-42.2 %-71.19 %
202368.62 %-75.4 %-79.83 %
202265.28 %-94.18 %-106.95 %
202163.85 %-99.97 %-112.97 %
202061.67 %-138.82 %-158.1 %
201960 %-124.01 %-195.53 %
201835.55 %-241.11 %-361.79 %
201759.53 %-398.12 %-640.71 %

TELA Bio Stock Sales Revenue, EBIT, Earnings per Share

The TELA Bio earnings per share therefore indicates how much revenue TELA Bio has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue TELA Bio earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates TELA Bio's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of TELA Bio’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating TELA Bio's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

TELA Bio Revenue, EBIT and net profit per share

DateTELA Bio Sales per ShareTELA Bio EBIT per shareTELA Bio Earnings per Share
2028e4.8 undefined0 undefined0.82 undefined
2027e3.89 undefined0 undefined0.3 undefined
2026e3.02 undefined0 undefined-0.25 undefined
2025e2.43 undefined0 undefined-0.66 undefined
2024e1.93 undefined0 undefined-1.38 undefined
20232.56 undefined-1.93 undefined-2.04 undefined
20222.55 undefined-2.4 undefined-2.72 undefined
20212.04 undefined-2.04 undefined-2.3 undefined
20201.41 undefined-1.96 undefined-2.23 undefined
20191.35 undefined-1.68 undefined-2.65 undefined
20180.75 undefined-1.81 undefined-2.72 undefined
20170.39 undefined-1.54 undefined-2.47 undefined

TELA Bio business model

TELA Bio Inc is an American medical technology company that specializes in the development and manufacture of innovative surgical implants. The history of this company began in 2012 when a group of experienced bioengineers and medical professionals decided to develop a better surgical tissue replacement material. The idea was to create a product that not only supports the healing process but is also safe, durable, and easy to handle. Over the years, TELA Bio has successfully implemented the business model of complete vertical integration, which means that the company takes care of everything from research and development to production, distribution, and marketing of its products. This allows the company to build closer relationships with its customers and improve the quality of its products by addressing the needs and requirements of its users. The core business of TELA Bio focuses on a wide range of surgical tissue replacement materials specifically designed for plastic and reconstructive surgery, hernia repair, and wound healing. These products are characterized by their high biocompatibility, strength, and flexibility, and provide a safe and effective solution for a variety of medical applications. Key products offered by TELA Bio include the OviTex® product family, which includes surgical mesh materials for supporting wound healing in hernia repairs and abdominal surgeries, as well as tissue replacement materials for breast reconstruction after mastectomy. These products are known for their high biocompatibility and ability to integrate into the surrounding tissue and restore natural tissue structures. In addition, TELA Bio also offers the TELADERM®-DH product, specifically developed for wound healing in diabetes patients. This product consists of a tissue replacement material that supports skin repair and reduces the risk of infection, particularly in patients with poorly healing wounds. Overall, TELA Bio has developed a wide range of products tailored to the needs of modern medicine. The company is focused on improving the quality of medical care and providing innovative solutions for surgical wound healing. With its successful implementations in research, production, and distribution, TELA Bio is well-positioned to continue growing and solidify its position as a leading provider of medical implants. TELA Bio is one of the most popular companies on Eulerpool.com.

TELA Bio SWOT Analysis

Strengths

TELA Bio Inc is positioned as a leading medical technology company specializing in advanced surgical solutions. The company's core strengths include:

TELA Bio offers a range of innovative surgical products tailored to meet the needs of healthcare professionals. These products have been developed based on extensive research and clinical data, ensuring their efficacy and safety.

TELA Bio has successfully established its presence in the market and has a strong track record of delivering high-quality solutions to healthcare providers. This track record helps build credibility and trust among potential customers.

Weaknesses

TELA Bio Inc has identified the following weaknesses that warrant attention:

Despite its achievements, TELA Bio has a relatively limited market reach, primarily due to intense competition and challenges in penetrating new markets. Expanding its reach and market share may require significant investments and strategic partnerships.

As a medical technology company, TELA Bio is highly dependent on regulatory approvals to bring its products to market. Delays or rejections in obtaining regulatory clearance may hinder the company's growth and expansion plans.

Opportunities

TELA Bio Inc can leverage the following opportunities to drive its future success:

There is an increasing demand for innovative surgical solutions that provide improved patient outcomes and reduced healthcare costs. TELA Bio can capitalize on this trend by continuously developing and introducing advanced products that address unmet medical needs.

TELA Bio can explore opportunities to expand its market presence in untapped geographical regions. By strategically identifying target markets and establishing strong distribution networks, the company can increase its reach and revenue potential.

Threats

TELA Bio Inc must be cautious of the following threats that may impact its business:

The medical technology industry is highly competitive, with numerous players vying for market share. TELA Bio faces the threat of competitors introducing similar or superior products, potentially reducing its market position.

Regulatory frameworks governing the medical technology sector may undergo changes, posing challenges for TELA Bio's product development and commercialization efforts. It is crucial for the company to stay updated with evolving regulations and adapt accordingly.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

TELA Bio Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

TELA Bio historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

TELA Bio shares outstanding

The number of shares was TELA Bio in 2024 — This indicates how many shares 22.869 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue TELA Bio earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates TELA Bio's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of TELA Bio’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating TELA Bio's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for TELA Bio.

TELA Bio latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2024-0.41 -0.42  (-1.82 %)2024 Q3
6/30/2024-0.48 -0.51  (-5.94 %)2024 Q2
3/31/2024-0.51 -0.23  (55.04 %)2024 Q1
12/31/2023-0.44 -0.53  (-19.5 %)2023 Q4
9/30/2023-0.5 -0.45  (10.29 %)2023 Q3
6/30/2023-0.54 -0.46  (15.39 %)2023 Q2
3/31/2023-0.57 -0.63  (-10.45 %)2023 Q1
12/31/2022-0.56 -0.52  (6.63 %)2022 Q4
9/30/2022-0.64 -0.64  (-0.31 %)2022 Q3
6/30/2022-0.63 -0.79  (-25.32 %)2022 Q2
1
2
3

Eulerpool ESG Scorecard© for the TELA Bio stock

Eulerpool World ESG Rating (EESG©)

48/ 100

🌱 Environment

54

👫 Social

42

🏛️ Governance

49

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

TELA Bio shareholders

%
Name
Stocks
Change
Date
10.43592 % EW Healthcare Partners4,110,709010/24/2024
7.18923 % Stonepine Capital Management, LLC2,831,8392,206,19410/23/2024
6.20885 % Nantahala Capital Management, LLC2,445,6671,347,8016/30/2024
3.55932 % Grow Funds LLC1,402,0171,402,0177/24/2024
3.40201 % Lytton (Laurence W)1,340,0521,340,0527/10/2024
3.18913 % Paradigm Capital Management, Inc.1,256,200740,9356/30/2024
3.13072 % AIGH Capital Management, LLC.1,233,189169,6076/30/2024
2.92458 % OrbiMed Advisors, LLC1,151,992-1,255,25010/25/2024
2.53872 % SilverArc Capital Management, LLC1,000,000223,1496/30/2024
2.29374 % The Vanguard Group, Inc.903,503-102,5496/30/2024
1
2
3
4
5
...
10

TELA Bio Executives and Management Board

Mr. Antony Koblish

(57)
TELA Bio President, Chief Executive Officer, Co-Founder, Director (since 2012)
Compensation 2.12 M

Mr. Roberto Cuca

(55)
TELA Bio Chief Financial Officer, Chief Operating Officer, Secretary
Compensation 1.02 M

Mr. Peter Murphy

(51)
TELA Bio Chief Commercial Officer
Compensation 936,762

Mr. Paul Talmo

(56)
TELA Bio Chief Strategic Officer
Compensation 858,262

Mr. Douglas Evans

(58)
TELA Bio Independent Chairman of the Board
Compensation 132,332
1
2

Most common questions regarding TELA Bio

What values and corporate philosophy does TELA Bio represent?

TELA Bio Inc represents a strong commitment to improving patient outcomes and quality of life through its innovative surgical reconstruction solutions. The company's corporate philosophy revolves around fostering partnerships with healthcare professionals and delivering unmatched value to both patients and providers. TELA Bio focuses on developing and commercializing advanced biomaterials and surgical implants, enabling surgeons to address complex soft tissue challenges effectively. With a dedication to research, development, and technological advancements, TELA Bio strives to create transformative medical solutions that support optimal patient healing and recovery.

In which countries and regions is TELA Bio primarily present?

TELA Bio Inc is primarily present in the United States.

What significant milestones has the company TELA Bio achieved?

TELA Bio Inc has achieved several significant milestones. Firstly, the company successfully completed its initial public offering (IPO) in February 2020, raising approximately $51 million. This marked a major achievement for TELA Bio Inc in terms of gaining access to public capital markets. Additionally, the company has received regulatory clearance for its OviTex portfolio of surgical implants, including OviTex PRS and OviTex RSM, which are used in various soft tissue reconstruction procedures. TELA Bio Inc has also experienced notable success in expanding its market presence and commercializing its products across the United States. These achievements demonstrate TELA Bio Inc's strong growth and determination in the medical technology field.

What is the history and background of the company TELA Bio?

TELA Bio Inc is a company specializing in surgical reconstruction and healing technologies. Founded in 2012, TELA Bio has quickly made a name for itself in the medical industry. Inspired by the groundbreaking research of scientists and surgeons, TELA Bio develops innovative products aimed at improving patient outcomes in soft tissue reconstruction. With a strong focus on bioengineering and advanced materials, TELA Bio's solutions are designed to address various surgical challenges effectively. TELA Bio Inc's dedication to innovation and commitment to patients has positioned them as a leading player in the field, providing healthcare professionals with cutting-edge solutions for better patient care.

Who are the main competitors of TELA Bio in the market?

The main competitors of TELA Bio Inc in the market include companies such as Johnson & Johnson, Medtronic, Integra LifeSciences, and Baxter International. These companies also operate in the medical technology industry and offer products and solutions that are similar to TELA Bio Inc. Competing against these established players, TELA Bio Inc strives to differentiate itself through innovative product offerings, advanced technologies, and a focus on meeting the specific needs of patients and healthcare providers.

In which industries is TELA Bio primarily active?

TELA Bio Inc is primarily active in the healthcare and medical device industry.

What is the business model of TELA Bio?

The business model of TELA Bio Inc focuses on developing and commercializing advanced surgical solutions for soft tissue reconstruction. By combining engineering innovation with proven biological constructs, TELA Bio aims to provide surgeons and patients with enhanced options for tissue repair and regeneration. TELA Bio's products, such as OviTex Reinforced BioScaffolds, offer a unique blend of biologic and synthetic materials to promote healing and improved patient outcomes. With a commitment to delivering high-quality, cost-effective solutions, TELA Bio strives to transform the landscape of soft tissue reconstruction and address unmet needs in various surgical specialties.

What is the P/E ratio of TELA Bio 2025?

The TELA Bio P/E ratio is -2.36.

What is the P/S ratio of TELA Bio 2025?

The TELA Bio P/S ratio is 0.64.

What is the Quality Investing of TELA Bio?

The Quality Investing for TELA Bio is 4/10.

What is the revenue of TELA Bio 2025?

The expected TELA Bio revenue is 95.66 M USD.

How high is the profit of TELA Bio 2025?

The expected TELA Bio profit is -25.91 M USD.

What is the business model of TELA Bio

The company TELA Bio Inc is a leading company in the field of biological tissue reconstruction and manufactures a wide range of innovative products. TELA Bio's business model is based on the development, manufacturing, and marketing of high-quality biotissue products used in the restoration and regeneration of tissues in the human body. TELA Bio's products include biological structures made from specially treated animal and/or plant skin. These structures are ideal for reconstructing damaged tissues such as muscle and fiber tissues and are used in various medical fields. The products are predominantly used in plastic and reconstructive surgery, general surgery, gynecology, and thoracic surgery. TELA Bio offers its customers a variety of products tailored to their specific requirements and needs. These include biological mesh structures that can be used in abdominal wall reconstruction or breast tissue restoration, as well as long-term replacement structures for connective tissue, muscles, or tendons. Additionally, TELA Bio also provides custom-made products specifically tailored to the individual needs of the patient. Another important aspect of TELA Bio's business model is its collaboration with doctors, medical professionals, and scientists. The company continually invests in research and development to improve and enhance its products. Through close collaboration with medical professionals, TELA Bio ensures that its products meet the highest quality and safety standards. TELA Bio also follows a clear growth strategy by continuously expanding its customer base and expanding its product range. The company has expanded its presence in the global market and distributes its products in Europe, Asia, and South America. As TELA Bio operates in a growing market, there are numerous opportunities for future growth and further expansion. Overall, TELA Bio's business model is characterized by a high level of innovation, close collaboration with medical professionals, and a clear growth strategy. Through the development and manufacturing of high-quality biotissue products, the company makes an important contribution to improving medical care and enhancing the quality of life for patients worldwide. Answer: TELA Bio Inc is a leading company in the field of biological tissue reconstruction. They develop, manufacture, and market high-quality biotissue products used in the restoration and regeneration of human tissues. These products are used in various medical fields including plastic and reconstructive surgery, general surgery, gynecology, and thoracic surgery. TELA Bio offers a wide range of products tailored to the specific needs of their customers. They collaborate with doctors, medical professionals, and scientists to ensure the highest quality and safety standards. TELA Bio also follows a clear growth strategy and has expanded its presence in the global market. They contribute to improving medical care and enhancing the quality of life for patients worldwide.

What is the TELA Bio dividend?

TELA Bio pays a dividend of 0 USD distributed over payouts per year.

How often does TELA Bio pay dividends?

The dividend cannot currently be calculated for TELA Bio or the company does not pay out a dividend.

What is the TELA Bio ISIN?

The ISIN of TELA Bio is US8723811084.

What is the TELA Bio WKN?

The WKN of TELA Bio is A2PUP9.

What is the TELA Bio ticker?

The ticker of TELA Bio is TELA.

How much dividend does TELA Bio pay?

Over the past 12 months, TELA Bio paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, TELA Bio is expected to pay a dividend of 0 USD.

What is the dividend yield of TELA Bio?

The current dividend yield of TELA Bio is .

When does TELA Bio pay dividends?

TELA Bio pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of TELA Bio?

TELA Bio paid dividends every year for the past 0 years.

What is the dividend of TELA Bio?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is TELA Bio located?

TELA Bio is assigned to the 'Health' sector.

Wann musste ich die Aktien von TELA Bio kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of TELA Bio from 2/9/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 2/9/2025.

When did TELA Bio pay the last dividend?

The last dividend was paid out on 2/9/2025.

What was the dividend of TELA Bio in the year 2024?

In the year 2024, TELA Bio distributed 0 USD as dividends.

In which currency does TELA Bio pay out the dividend?

The dividends of TELA Bio are distributed in USD.

All fundamentals about TELA Bio

Our stock analysis for TELA Bio Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of TELA Bio Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.